Multiple validated measures of adherence indicate high levels of adherence to generic HIV antiretroviral therapy in a resource-limited setting

Jessica H. Oyugi, Jayne Byakika-Tusiime, Edwin D. Charlebois, Cissy Kityo, Roy Mugerwa, Peter Mugyenyi, David Bangsberg

Research output: Contribution to journalArticle

223 Citations (Scopus)

Abstract

Background: There are no validated measures of adherence to HIV antiretroviral therapy in resource-poor settings. Such measures are essential to understand the unique barriers to adherence as access to HIV antiretroviral therapy expands. Methods: We assessed correspondence between multiple measures of adherence and viral load suppression in 34 patients purchasing generic Triomune antiretroviral therapy (coformulated stavudine, lamivudine, and nevirapine; CIPLA, Ltd., Mumbai, India) in Kampala, Uganda. Measures included 3-day patient self-report, 30-day visual analog scale, electronic medication monitoring, and unannounced home pill count. HIV-1 load was determined at baseline and 12 weeks. Results: Mean adherence was 91%-94% by all measures. Seventy-six percent of subjects had a viral load of <400 copies/mL at 12 weeks. All measures were closely correlated with each other (R = 0.77-0.89). Each measure was also significantly associated with 12-week HIV load. There was no significant difference between patient-reported and objective measures of adherence. Conclusions: This sample of patients purchasing generic HIV antiretroviral therapy has among the highest measured adherence reported to date. Patient-reported measures were closely associated with objective measures. The relative ease of administration of the 30-day visual analog scale suggests that this may be the preferred method to assess adherence in resource-poor settings.

Original languageEnglish (US)
Pages (from-to)1100-1102
Number of pages3
JournalJournal of Acquired Immune Deficiency Syndromes
Volume36
Issue number5
DOIs
StatePublished - Aug 15 2004
Externally publishedYes

Fingerprint

HIV
Viral Load
Visual Analog Scale
Therapeutics
Uganda
Self Report
HIV-1
India
stavudine, lamivudine, nevirapine drug combination

ASJC Scopus subject areas

  • Virology
  • Immunology

Cite this

Multiple validated measures of adherence indicate high levels of adherence to generic HIV antiretroviral therapy in a resource-limited setting. / Oyugi, Jessica H.; Byakika-Tusiime, Jayne; Charlebois, Edwin D.; Kityo, Cissy; Mugerwa, Roy; Mugyenyi, Peter; Bangsberg, David.

In: Journal of Acquired Immune Deficiency Syndromes, Vol. 36, No. 5, 15.08.2004, p. 1100-1102.

Research output: Contribution to journalArticle

Oyugi, Jessica H. ; Byakika-Tusiime, Jayne ; Charlebois, Edwin D. ; Kityo, Cissy ; Mugerwa, Roy ; Mugyenyi, Peter ; Bangsberg, David. / Multiple validated measures of adherence indicate high levels of adherence to generic HIV antiretroviral therapy in a resource-limited setting. In: Journal of Acquired Immune Deficiency Syndromes. 2004 ; Vol. 36, No. 5. pp. 1100-1102.
@article{751ae5b85e6743bd8a7a57966a55ae89,
title = "Multiple validated measures of adherence indicate high levels of adherence to generic HIV antiretroviral therapy in a resource-limited setting",
abstract = "Background: There are no validated measures of adherence to HIV antiretroviral therapy in resource-poor settings. Such measures are essential to understand the unique barriers to adherence as access to HIV antiretroviral therapy expands. Methods: We assessed correspondence between multiple measures of adherence and viral load suppression in 34 patients purchasing generic Triomune antiretroviral therapy (coformulated stavudine, lamivudine, and nevirapine; CIPLA, Ltd., Mumbai, India) in Kampala, Uganda. Measures included 3-day patient self-report, 30-day visual analog scale, electronic medication monitoring, and unannounced home pill count. HIV-1 load was determined at baseline and 12 weeks. Results: Mean adherence was 91{\%}-94{\%} by all measures. Seventy-six percent of subjects had a viral load of <400 copies/mL at 12 weeks. All measures were closely correlated with each other (R = 0.77-0.89). Each measure was also significantly associated with 12-week HIV load. There was no significant difference between patient-reported and objective measures of adherence. Conclusions: This sample of patients purchasing generic HIV antiretroviral therapy has among the highest measured adherence reported to date. Patient-reported measures were closely associated with objective measures. The relative ease of administration of the 30-day visual analog scale suggests that this may be the preferred method to assess adherence in resource-poor settings.",
author = "Oyugi, {Jessica H.} and Jayne Byakika-Tusiime and Charlebois, {Edwin D.} and Cissy Kityo and Roy Mugerwa and Peter Mugyenyi and David Bangsberg",
year = "2004",
month = "8",
day = "15",
doi = "10.1097/00126334-200408150-00014",
language = "English (US)",
volume = "36",
pages = "1100--1102",
journal = "Journal of Acquired Immune Deficiency Syndromes",
issn = "1525-4135",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Multiple validated measures of adherence indicate high levels of adherence to generic HIV antiretroviral therapy in a resource-limited setting

AU - Oyugi, Jessica H.

AU - Byakika-Tusiime, Jayne

AU - Charlebois, Edwin D.

AU - Kityo, Cissy

AU - Mugerwa, Roy

AU - Mugyenyi, Peter

AU - Bangsberg, David

PY - 2004/8/15

Y1 - 2004/8/15

N2 - Background: There are no validated measures of adherence to HIV antiretroviral therapy in resource-poor settings. Such measures are essential to understand the unique barriers to adherence as access to HIV antiretroviral therapy expands. Methods: We assessed correspondence between multiple measures of adherence and viral load suppression in 34 patients purchasing generic Triomune antiretroviral therapy (coformulated stavudine, lamivudine, and nevirapine; CIPLA, Ltd., Mumbai, India) in Kampala, Uganda. Measures included 3-day patient self-report, 30-day visual analog scale, electronic medication monitoring, and unannounced home pill count. HIV-1 load was determined at baseline and 12 weeks. Results: Mean adherence was 91%-94% by all measures. Seventy-six percent of subjects had a viral load of <400 copies/mL at 12 weeks. All measures were closely correlated with each other (R = 0.77-0.89). Each measure was also significantly associated with 12-week HIV load. There was no significant difference between patient-reported and objective measures of adherence. Conclusions: This sample of patients purchasing generic HIV antiretroviral therapy has among the highest measured adherence reported to date. Patient-reported measures were closely associated with objective measures. The relative ease of administration of the 30-day visual analog scale suggests that this may be the preferred method to assess adherence in resource-poor settings.

AB - Background: There are no validated measures of adherence to HIV antiretroviral therapy in resource-poor settings. Such measures are essential to understand the unique barriers to adherence as access to HIV antiretroviral therapy expands. Methods: We assessed correspondence between multiple measures of adherence and viral load suppression in 34 patients purchasing generic Triomune antiretroviral therapy (coformulated stavudine, lamivudine, and nevirapine; CIPLA, Ltd., Mumbai, India) in Kampala, Uganda. Measures included 3-day patient self-report, 30-day visual analog scale, electronic medication monitoring, and unannounced home pill count. HIV-1 load was determined at baseline and 12 weeks. Results: Mean adherence was 91%-94% by all measures. Seventy-six percent of subjects had a viral load of <400 copies/mL at 12 weeks. All measures were closely correlated with each other (R = 0.77-0.89). Each measure was also significantly associated with 12-week HIV load. There was no significant difference between patient-reported and objective measures of adherence. Conclusions: This sample of patients purchasing generic HIV antiretroviral therapy has among the highest measured adherence reported to date. Patient-reported measures were closely associated with objective measures. The relative ease of administration of the 30-day visual analog scale suggests that this may be the preferred method to assess adherence in resource-poor settings.

UR - http://www.scopus.com/inward/record.url?scp=3342913622&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3342913622&partnerID=8YFLogxK

U2 - 10.1097/00126334-200408150-00014

DO - 10.1097/00126334-200408150-00014

M3 - Article

VL - 36

SP - 1100

EP - 1102

JO - Journal of Acquired Immune Deficiency Syndromes

JF - Journal of Acquired Immune Deficiency Syndromes

SN - 1525-4135

IS - 5

ER -